Amneal Launches PEMRYDI RTU, The First Ready-To-Use Version Of Important Oncology Injectable Medicine
Portfolio Pulse from Benzinga Newsdesk
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) launched PEMRYDI RTU, the first ready-to-use pemetrexed injectable for non-squamous non-small cell lung cancer and malignant pleural mesothelioma, eliminating the need for reconstitution, dilution, or refrigeration. This launch is part of Amneal's strategy to release two to three branded oncology 505(b)(2) products annually, starting in 2024. PEMRYDI RTU has a unique J-Code (J9324) for reimbursement and is available in two vial sizes. It's indicated for use with pembrolizumab and platinum chemotherapy or cisplatin. U.S. annual sales for pemetrexed were $287 million for the 12 months ending February 2024.
April 16, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amneal Pharmaceuticals, Inc. launches PEMRYDI RTU, the first ready-to-use injectable for certain cancers, aiming to release more oncology products annually. U.S. sales for pemetrexed hit $287 million in the past year.
The launch of PEMRYDI RTU represents a significant advancement in the treatment options available for non-squamous non-small cell lung cancer and malignant pleural mesothelioma, potentially leading to increased market share and revenue for Amneal. Given the product's unique ready-to-use formulation, it addresses specific needs in the oncology care sector, likely resulting in positive reception from healthcare providers and patients. The strategic focus on developing and launching two to three oncology 505(b)(2) products annually starting in 2024 indicates a strong commitment to the oncology segment, which could further enhance Amneal's growth prospects in this area.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100